849766-53-6

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 4-[(4-chloro-3-fluorophenyl)methyl]-, 1,1-dimethylethyl ester
• CAS NO: 849766-53-6
• Molecular Formula: C17H23ClFNO2
• Molecular Weight: 327.827
• Mol File: 849766-53-6.mol
• Article Data: 8

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 4-[(4-chloro-3-fluorophenyl)methyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 4-[(4-chloro-3-fluorophenyl)methyl]-, 1,1-dimethylethyl ester(849766-53-6)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 4-[(4-chloro-3-fluorophenyl)methyl]-, 1,1-dimethylethyl ester(849766-53-6)

Safety Data

• Hazardous Substances Data: 849766-53-6(Hazardous Substances Data)

Upstream product

• 60811-18-9 2-chloro-5-bromofluorobenzene 
• 159635-49-1 tert-butyl 4-methylidenepiperidine-1-carboxylate 
• 202982-67-0 1-chloro-2-fluoro-4-iodo-benzene 
• 174701-71-4 (4-chloro-3-fluorobenzyl)-triphenylphosphonium bromide 
• 206362-80-3 4-(bromomethyl)-1-chloro-2-fluorobenzene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Downstream Products

• 849766-58-1 4-(4-chloro-3-fluorobenzyl)piperidine 

Relevant articles and documents

The development of HEC-866 and its analogues for the treatment of idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a typical survival time between three to five years. Two drugs, pirfenidone and nintedanib have been approved for the treatment of IPF, but they have limited efficacy. Thus, th

SULFONYL PIPERIDINE DERIVATIVES AND THEIR USE FOR TREATING PROKINETICIN MEDIATED GASTROINTESTINAL DISORDERS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof (Formula (I)) in which m, n, W, X, Y, Z, R1, R22, R3, R4 and R5 are as defined in the specificatio

1-SULFONYL PIPERIDINE DERIVATIVES AS MODULATORS OF PROKINETICIN RECEPTORS

The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof in which m, n, W, X, Y, Z, R1 , R2, R3, R4 and R5 are as defined in the specification, composition